TURCO, FABIO
 Distribuzione geografica
Continente #
NA - Nord America 431
EU - Europa 326
AS - Asia 190
OC - Oceania 6
AF - Africa 4
SA - Sud America 1
Totale 958
Nazione #
US - Stati Uniti d'America 412
IT - Italia 120
IE - Irlanda 78
CN - Cina 53
SG - Singapore 40
SE - Svezia 38
IN - India 22
GB - Regno Unito 20
HK - Hong Kong 20
CA - Canada 16
ES - Italia 13
IR - Iran 13
JP - Giappone 12
BE - Belgio 7
CH - Svizzera 7
CZ - Repubblica Ceca 7
DE - Germania 7
KR - Corea 7
NL - Olanda 7
TR - Turchia 7
FI - Finlandia 6
PH - Filippine 6
PL - Polonia 6
AU - Australia 5
FR - Francia 5
NG - Nigeria 4
MO - Macao, regione amministrativa speciale della Cina 3
MX - Messico 3
MY - Malesia 3
HU - Ungheria 2
VN - Vietnam 2
AE - Emirati Arabi Uniti 1
AT - Austria 1
BO - Bolivia 1
HR - Croazia 1
NZ - Nuova Zelanda 1
TH - Thailandia 1
UA - Ucraina 1
Totale 958
Città #
Chandler 113
Dublin 78
Turin 42
Nyköping 34
Singapore 26
Ashburn 11
Hong Kong 11
Milan 10
Genoa 9
London 9
Medford 9
New York 9
Princeton 9
Hangzhou 8
Seattle 8
Los Angeles 7
Madrid 7
Tokyo 7
Shanghai 6
Torino 6
Hyderabad 5
Isfahan 5
Lappeenranta 5
Abuja 4
Beijing 4
Chennai 4
La Quinta 4
Molenbeek-Saint-Jean 4
Moncalieri 4
Montreal 4
Seoul 4
Toronto 4
Ankara 3
Brno 3
Chengdu 3
Chicago 3
Coventry 3
Dagupan 3
Fairfield 3
Frankfurt am Main 3
Guangzhou 3
Guwahati 3
Hebei 3
Liverpool 3
Macao 3
Nanaimo 3
Petaling Jaya 3
Rome 3
Rutherford 3
Sydney 3
Vezia 3
Wilmington 3
Barletta 2
Belfast 2
Boardman 2
Buffalo 2
Catania 2
Changsha 2
Croydon 2
Dalian 2
Davao City 2
Devrek 2
Dong Ket 2
Edmonton 2
Ferrol 2
Gdynia 2
Germantown 2
Ghent 2
Guadalajara 2
Guadix 2
Guiyang 2
Hawthorne 2
Hoover 2
Hradec Králové 2
Istanbul 2
Johnston 2
Kolkata 2
Krakow 2
Leipzig 2
Maastricht 2
Maniowy 2
Marseille 2
Milwaukee 2
Mumbai 2
Nagytarcsa 2
New Delhi 2
Nijmegen 2
Omaha 2
Paris 2
Pierrefonds 2
Redmond 2
San Marcos 2
Seocho-gu 2
Trento 2
Vigo 2
Virginia Beach 2
Wuhan 2
Zurich 2
Adelaide 1
Alessandria 1
Totale 624
Nome #
Renal cell carcinoma (RCC): Fatter is better? A review on the role of obesity in RCC 223
Prognostic role of the duration of response to androgen deprivation therapy in patients with metastatic castration resistant prostate cancer treated with enzalutamide or abiraterone acetate 86
Antibody-Drug Conjugates in Urothelial Carcinoma: A New Therapeutic Opportunity Moves from Bench to Bedside 53
Bipolar androgen therapy in prostate cancer: Current evidences and future perspectives 48
Treatment Landscape for Patients with Castration-Resistant Prostate Cancer: Patient Selection and Unmet Clinical Needs 40
Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with metastatic castration resistant prostate cancer treated with Abiraterone or Enzalutamide 40
Prognostic factors in metastatic castration resistant prostate cancer patients treated with Radium-223: a retrospective study 40
Role of radium-223 discontinuation due to adverse events in castration-resistant prostate cancer patients. A retrospective monocentric analysis 39
Are tyrosine kinase inhibitors an effective treatment in testicular metastases from kidney cancer? Case report 38
Prognostic role of early PSa drop in castration resistant prostate cancer patients treated with abiraterone acetate or enzalutamide 33
New emerging targets in advanced urothelial carcinoma: Is it the primetime for personalized medicine? 33
Metastatic Urothelial Carcinoma: Have We Take the Road to the Personalized Medicine? 31
Interactions between androgen receptor signaling and other molecular pathways in prostate cancer progression: Current and future clinical implications 30
Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16) 29
Therapeutic sequencing in advanced renal cell carcinoma: how to choose considering clinical and biological factors 28
Darolutamide in Metastatic Prostate Cancer 26
Treatment intensification for metastatic prostate cancer: New treatment landscapes in androgen deprivation-based therapy 26
New Perspectives in the Medical Treatment of Non-Muscle-Invasive Bladder Cancer: Immune Checkpoint Inhibitors and Beyond 24
Adverse event assessment in prostate cancer patients receiving androgen deprivation therapy: are we doing enough? 24
How to Improve the Quality of Life of Patients with Prostate Cancer Treated with Hormone Therapy? 18
Short-Term Safety and Psychosocial Impact of the BNT162b2 mRNA COVID-19 Vaccine in Cancer Patients-An Italian Single-Center Experience 17
How Does Environmental and Occupational Exposure Contribute to Carcinogenesis in Genitourinary and Lung Cancers? 16
Addition of New Androgen Receptor Pathway Inhibitors to Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Metanalysis 13
Navigating the ICI Combination Treatment Journey: Patterns of Response and Progression to First-Line ICI-Based Combination Treatment in Metastatic Renal Cell Carcinoma 10
Time trends in health-related quality of life assessment and reporting within publications of oncology randomised phase III trials: a meta-research study 8
Synthetic Lethality by Co-Inhibition of Androgen Receptor and Polyadenosine Diphosphate-Ribose in Metastatic Prostate Cancer 7
TEAM Study: Upfront Docetaxel Treatment in Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Real-World, Multicenter, Retrospective Analysis 6
Safety profile of darolutamide versus placebo: a systematic review and meta-analysis 3
Treatment options in first-line metastatic renal carcinoma: A meta-analysis of 2556 patients treated with immune checkpoint inhibitors-based combinations in randomised controlled trials 2
Totale 991
Categoria #
all - tutte 6.020
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.020


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202111 0 0 0 0 0 0 1 1 3 1 2 3
2021/2022103 12 2 5 1 4 0 2 0 6 8 38 25
2022/2023534 30 51 15 27 49 104 40 45 61 39 35 38
2023/2024309 36 48 21 38 11 28 22 14 9 31 16 35
2024/202534 31 3 0 0 0 0 0 0 0 0 0 0
Totale 991